NSABP C-14
NSABP C-14
CORRECT- MRD II: Second COloRectal cancer clinical validation study to predict REcurrence using a Circulating Tumor DNA assay to detect Minimal Residual Disease.
Protocol Chair: Mohamed Salem, MD
Protocol Officer: Shannon Puhalla, MD
Patient Population:
colorectal
Target Accrual: 750 patients
Status: Recruiting
ClinicialTrials.gov Identifier: NCT05210283
CORRECT- MRD II: Second COloRectal cancer clinical validation study to predict REcurrence using a Circulating Tumor DNA assay to detect Minimal Residual Disease.
Protocol Chair: Mohamed Salem, MD
Protocol Officer: Shannon Puhalla, MD
Patient Population:
colorectal
Target Accrual: 750 patients
Status: Recruiting
ClinicialTrials.gov Identifier: NCT05210283